Syntax Bio
Focus: Syntax Bio is a public biotechnology company focused on iPSC (induced pluripotent stem cell) manufacturing technology, positioned to enable cell therapy and oncology applications. The company operates at a relatively early stage with limited publicly disclosed commercial products.
Profile data last refreshed 13h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
3-1 this month
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Should You Work at Syntax Bio?
AI assessmentSyntax Bio is a speculative, technology-platform play suited for scientists/engineers betting on iPSC manufacturing disruption, not for those seeking near-term clinical validation or revenue visibility.
Why Work Here
- Working on cutting-edge iPSC manufacturing technology with applications in high-growth cell therapy and oncology segments
- Public company status provides liquidity and stability compared to private biotech, with potential for equity upside
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Syntax Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.